Marc Darrow, MD, JD

A patient with a kneecap that keeps slipping may ask whether regenerative treatment could help the damaged supporting tissues. Another patient may have persistent pain behind the kneecap after a previous dislocation, without further slipping. These are related concerns, but they do not call for the same explanation or necessarily the same treatment.

My starting point is to identify what is causing the symptoms: recurrent mechanical instability, irritated or damaged cartilage, a painful tendon, or a combination. The treatment name—PRP, bone marrow concentrate, donated umbilical cord tissue, or exosomes—cannot answer that diagnostic question.

Donated cord tissue and cell-derived signaling are important areas of orthopedic research. Their most plausible role in this discussion concerns the biological environment of injured or degenerating tissues. Current evidence does not establish that they prevent recurrent kneecap dislocation. Understanding both the possibilities and the limits helps put these approaches in their proper context.

What is patellar instability?

The patella, or kneecap, moves within the trochlear groove at the lower end of the femur as the knee bends and straightens. Its stability depends on the shape and alignment of the bones, ligament restraints, and muscular control. The medial patellofemoral ligament (MPFL) helps resist excessive outward movement, particularly near knee extension. (1)

  • Subluxation: the kneecap partly slips out of its normal alignment.
  • Dislocation: the kneecap completely leaves the groove, usually toward the outside of the knee.
  • Maltracking: the kneecap follows an abnormal path as the knee moves; this does not always produce a complete dislocation.
  • Patellofemoral pain: pain around or behind the kneecap that can occur without a dislocation.

A twisting injury with the foot planted, a fall, or a direct impact may initiate a dislocation. A relatively minor movement can also provoke an episode when predisposing anatomy or tissue laxity is present. These situations should not all be attributed to degenerative wear. (1)

A new dislocation needs assessment for associated injury

A kneecap that remains visibly displaced needs prompt medical treatment. A cold or numb foot, major trauma, or inability to straighten the knee also warrants urgent evaluation. A patellar dislocation differs from a tibiofemoral knee dislocation, which can threaten blood supply to the leg.

Even if the kneecap returns to position, the injury may damage cartilage or detach a fragment of cartilage and bone. A locked knee or substantial swelling can signal more than a stretched ligament. The British Orthopaedic Association recommends radiographs after reduction and MRI when associated injury is suspected, assessment is difficult, recovery is poor, or surgery is being considered. (2)

The ESSKA consensus takes a broader approach to MRI after a first dislocation, emphasizing its role in detecting osteochondral injury and predisposing anatomy. These recommendations differ in scope, but both support checking for important damage rather than assuming that a reduced kneecap means the injury has resolved. (1)

Why does the kneecap keep dislocating?

The likelihood of recurrence varies. A systematic review of 17 studies reported an overall redislocation rate of 33.6% after a first lateral dislocation. Younger age, open growth plates, a shallow or abnormal trochlear groove, a high-riding patella, and an increased tibial tubercle–trochlear groove distance were associated with greater risk. Multiple risk factors increased that risk further. These pooled figures describe groups, not an individual prognosis. (3)

A separate 2022 study followed 201 patients after nonoperative treatment; 115 experienced recurrence within two years. Age under 16, instability in the other knee, and trochlear dysplasia were important predictors in that cohort. The higher recurrence rate does not contradict the pooled estimate: populations and risk profiles differ. Its prediction model also needs to be interpreted in the setting in which it was developed. (4)

This is why an apparently similar dislocation can lead to different recommendations in two patients. The history, examination, skeletal maturity, and anatomy all matter.

Hypermobility and hypermobile Ehlers-Danlos syndrome

Generalized joint hypermobility can reduce the passive restraint provided by ligaments. A 2024 systematic review found an association between hypermobility and patellar instability, although the evidence was low quality. Some included studies also reported greater failure risk or less favorable outcomes after stabilization in patients with Ehlers-Danlos syndrome. (5)

That does not mean every hypermobile patient has hEDS, or that surgery will fail in every patient with EDS. It means tissue laxity and the broader clinical picture deserve attention when assessing recurrence risk and selecting treatment. Repeated dislocations that a person can reduce themselves still warrant evaluation.

MRI findings do not always explain the symptoms

Imaging is valuable for identifying damaged cartilage, loose fragments, ligament injury, and anatomical risk factors. It cannot substitute for understanding what the patient experiences.

A 2025 study of 75 adolescents with previous patellar dislocation found no correlation between commonly used radiological measurements and patient-reported outcome scores. Bone measurements therefore did not reliably describe subjective knee health in that sample. The study did not show that imaging is unnecessary or that anatomical risk factors have no relevance to future dislocation. (6)

An apparent meniscal tear after dislocation may need a closer look

A 2024 study examined 44 dislocation cases in 42 patients undergoing MPFL reconstruction. Twenty-seven cases showed abnormal signal in the anterior horn of the lateral meniscus, including ten with grade 3 changes. Yet no corresponding meniscal tears were identified at arthroscopy. (7)

This is a useful warning against treating an MRI phrase as the diagnosis by itself. It does not mean meniscal tears never accompany a patellar dislocation. The imaging pattern, examination, symptoms, and circumstances of injury need to fit together.

What can nonsurgical treatment accomplish?

Nonoperative care can be appropriate after a first dislocation, particularly when there is no fragment requiring treatment and recurrence risk is lower. The 2025 ESSKA treatment consensus favors individualized decisions rather than a universal rule that all first dislocations receive the same care. Higher-risk patients and those with persistent symptoms may warrant an earlier surgical discussion. (8)

Rehabilitation commonly addresses swelling, knee motion, quadriceps and hip strength, balance, movement control, and confidence. Bracing may offer short-term comfort or support, but strong evidence that a brace prevents future dislocation is lacking. Rehabilitation remains important whether treatment is surgical or nonsurgical. (8)

The hamstrings and the rest of the leg matter too

A 2021 pilot study identified reduced knee-flexor strength in both legs of patients with recurrent patellar instability. This supports assessing the hamstrings as well as the quadriceps. However, the study could not determine whether weakness preceded the dislocations, developed afterward, or reflected both processes. It did not prove that hamstring strengthening alone prevents recurrence. (9)

A 2022 systematic review also identified altered gait patterns, including slower walking and shorter strides, with variable changes at the hip, knee, and ankle. There was no single pattern shared by every patient. Rehabilitation should therefore respond to demonstrated deficits rather than assuming that everyone needs the same correction. (10)

Blood-flow restriction training: a research question, not a proven solution

Blood-flow restriction training uses an external cuff during low-load exercise to increase muscular training stimulus. The BRAINS paper cited in discussions of patellar instability describes a randomized trial designed to test this approach; it is a protocol, not a report showing that the intervention works. (11)

As of this review, its ClinicalTrials.gov record, NCT04554212, lists the study as recruiting with no posted results. It should not be presented as established protection against redislocation or later arthritis. Clinical screening and supervision are necessary when this approach is considered.

When should surgery be discussed?

Surgical assessment may be appropriate for a repairable osteochondral fragment, recurrent instability, or ongoing symptoms with substantial recurrence risk. An operation is not reserved only for a kneecap that can no longer be put back in place. The proposed procedure should address the identified instability mechanism. (8)

A 2023 Cochrane review judged the comparative evidence for surgery versus nonsurgical treatment to be very low certainty. This limits confidence in broad claims about which approach is best for everyone. Much of the evidence concerned first-time dislocations, with insufficient rigorous randomized evidence for recurrent cases at that time. (12)

A critically appraised topic published online in 2024 and in a 2025 journal issue found evidence favoring MPFL surgery for lower redislocation rates, with less consistent findings for patient-perceived function. Differences in study selection and methods help explain why its conclusions were more favorable than the Cochrane assessment. (13)

New 2026 randomized trial: better stability does not guarantee better symptom scores

A randomized trial enrolled 61 patients aged 12–30 with recurrent lateral dislocation and without selected high-risk anatomical features. Both groups underwent arthroscopy and rehabilitation; one also received isolated MPFL reconstruction. At three years, persistent subjective instability was reported in 16.7% of the reconstruction group versus 53.6% of assessed controls. (14)

Both groups improved on patient-reported measures, without significant between-group differences in those scores. Reconstruction reduced instability in this selected population, but did not clearly outperform the comparison for every measure of symptoms or function. The small sample and exclusion of certain high-risk anatomy limit generalization. The control group also underwent arthroscopy, so this was not a comparison against rehabilitation with no procedure. (14)

What do the different stabilization operations do?

MPFL reconstruction uses a graft to restore medial restraint. It is commonly considered for recurrent lateral instability and is not dependent solely on finding a complete ligament tear. Tibial tubercle osteotomy repositions the bony attachment of the patellar tendon on the tibia—the shinbone—to modify alignment or loading in selected patients. It does not reshape the lower end of the thighbone. Trochleoplasty changes the shape of the femoral groove and is reserved for selected anatomical problems. (15)

Isolated lateral release is not recommended as a general treatment for patellar instability. Releasing lateral restraint without addressing the underlying problem may worsen instability. Lateral lengthening or release can have a selected adjunctive role when genuine lateral tightness is present. Retinacular imbrication, by contrast, folds and tightens tissue; it does not loosen it. (15)

Trochleoplasty: lower recurrence must be weighed against complications

A systematic review covering 1,000 trochleoplasties found low redislocation rates, but also reported stiffness, subsequent surgery, and patellofemoral osteoarthritis across the included studies. Results varied substantially. Much of the evidence was observational, and combined procedures make it difficult to attribute outcomes to trochleoplasty alone. (16)

These findings support a careful discussion of potential benefits and harms. They do not establish that all stabilization surgery causes arthritis or that every patient with trochlear dysplasia needs this operation.

Military outcomes show why return to full activity is a separate outcome

In a 2022 series of 51 patients treated with a combined stabilization procedure, 7.8% reported redislocation, while 49% reported lower activity than before injury and 19.6% reported restrictions in daily activities. (17)

The demanding military population and specific combined procedure limit application to other patients. Nevertheless, the study illustrates a useful distinction: reducing redislocation does not necessarily restore unrestricted performance or eliminate pain.

Where do regenerative treatments fit after patellar dislocation?

After the acute injury has been assessed, persistent symptoms may reflect more than instability alone. Cartilage damage, joint inflammation, and painful surrounding tissues can coexist with a previous MPFL injury. Researchers are studying biologics for some of these associated problems. The evidence must match the tissue, preparation, and outcome being discussed.

A 2025 systematic review of PRP for patellofemoral arthritis, chondromalacia, and anterior knee pain included five studies and 146 patients. Clinical scores improved, but evidence of cartilage regeneration was limited and uncertain. That research does not establish restoration of ligament restraint or prevention of another dislocation. (18)

A 2026 review of nine studies of PRP-based and cell-containing preparations for patellofemoral cartilage disease or osteoarthritis also found encouraging symptom results alongside substantial methodological limitations. These findings justify further research, rather than a claim that all biologic products work equally well. (19)

Donated umbilical cord tissue: what are the possibilities?

Donated umbilical cord tissue is obtained after birth with appropriate consent and screening. Wharton’s jelly is the connective tissue surrounding the cord’s blood vessels. It is different from cord blood, from a patient’s own bone marrow, and from an isolated exosome preparation.

Its extracellular matrix contains components such as collagen, hyaluronic acid, and proteoglycans. These give researchers reasons to study its interactions with injured tissues and its possible use as a scaffold or carrier of biological signals. A matrix-based preparation should not automatically be described as an injection of large numbers of living stem cells: processing and storage affect its composition. A 2026 analysis emphasized this distinction between minimally manipulated tissue products and isolated cellular therapies. (20)

The practical research possibilities include influencing inflammatory signaling, supporting interactions between resident cells and their surrounding matrix, and developing materials that assist tissue repair. These are different questions from whether a tissue injection can recreate an MPFL or correct abnormal bone alignment.

Laboratory research: what has actually been measured in Wharton’s jelly?

A 2020 study characterized a processed Wharton’s jelly formulation obtained from donated umbilical cords. The investigators detected growth factors, inflammatory and anti-inflammatory signaling proteins, hyaluronic acid, and membrane-enclosed particles consistent with extracellular vesicles. This provides a biological rationale for studying how such preparations interact with injured tissue. (21)

However, it was a laboratory characterization study, not a trial showing that patients improved. Detecting a molecule does not establish an effective dose, clinical potency, or superiority to PRP. Detecting vesicles does not establish that all particles are therapeutically active exosomes. The authors disclosed commercial relationships with the formulation developer. These findings apply to the formulation tested and cannot be assumed for every donated cord product.

Human Wharton’s jelly evidence already discussed on our site

Our comparison of PRP, bone marrow, and Wharton’s jelly for knee pain discusses a published case report involving a 27-year-old man with grade II knee osteoarthritis. Pain decreased by 50% over three months after a cord-derived Wharton’s jelly preparation, with improvements in patient-reported measures. X-rays did not establish cartilage restoration. (22)

This is an encouraging observation for symptom research. A single case cannot establish comparative effectiveness, exclude placebo effects, or predict the outcome in an adolescent with recurrent patellar instability.

A 55-patient tissue-allograft study offers a larger, but still preliminary, signal

A 2022 observational study followed 55 patients aged 56–93 with knee osteoarthritis for 90 days after a cryopreserved umbilical cord/Wharton’s jelly tissue allograft application. Pain, stiffness, and function scores improved, and no adverse events were reported during the observation period. (23)

There was no randomized control group, follow-up was short, and the manufacturer was involved in design, analysis, writing, and the publication decision. The study therefore cannot establish how much improvement was attributable to the allograft, prove long-term safety, or demonstrate that it regenerates cartilage. It also did not test patellar redislocation. These limitations do not erase the findings; they define what the findings can support.

A 2022 review of donated cord-tissue preparations

Gupta and Maffulli reviewed minimally manipulated umbilical cord-tissue formulations for knee osteoarthritis. They described the tissue’s biological components and preliminary clinical reports of pain and functional improvement, while emphasizing the need for larger, appropriately powered investigations. (24)

This supports continued interest in donated tissue as a research direction. The review includes the same Wharton’s jelly case report discussed above, so it should not be counted as a separate successful clinical trial. It does not establish that tissue injections rebuild patellar restraints.

A 2024 review: encouraging possibilities, but different products must stay distinct

A review in British Medical Bulletin evaluated laboratory, preclinical, and human evidence on Wharton’s jelly and related cell preparations for knee osteoarthritis. Its authors considered the field promising but described effectiveness as controversial and called for adequately powered randomized trials. (25)

The review covers both tissue preparations and isolated cells. Its favorable findings cannot all be attributed to a non-expanded donated tissue product. Here, it is used to explain the research landscape, rather than to transfer results from culture-expanded MSC treatments to Wharton’s jelly allografts. Knee-OA findings also cannot establish prevention of patellar dislocation.

What the Wharton’s jelly research supports at each level

Research What it contributes What remains unanswered
2020 formulation analysis (21) Identifies biological components in one tested preparation Whether those components improve patient outcomes
2021 knee-OA case report (22) One patient’s symptom response Comparative effectiveness and reproducibility
2022 observational study, 55 patients (23) Short-term pain, stiffness, and function observations Benefit over placebo and long-term safety
2024 review (25) Maps tissue, cell, and preclinical research Effectiveness of a specific non-expanded allograft
2026 composition analysis (20) Clarifies tissue matrix versus viable cellular products Clinical benefit in recurrent patellar instability

The research therefore offers reasons to investigate symptom relief and tissue-support mechanisms. It has not established that a Wharton’s jelly injection restores MPFL strength, corrects patellar alignment, or prevents repeat dislocation.

What ongoing research could clarify

The registry record for NCT06608134 describes a dose-ranging safety and feasibility study of Wharton’s jelly allograft for knee osteoarthritis. It lists recruiting status, based on its last update in September 2024, and no posted results as checked for this article. A separate planned comparison with hyaluronic acid and saline, NCT04711304, has an unknown current status and no posted results. An estimated completion date should not be mistaken for a successful completed trial.

Controlled studies with clearly characterized products could help determine whether symptom improvement exceeds placebo, how durable it is, and which patients might benefit. Studies would need to measure instability and repeat dislocations specifically before making a stabilization claim.

Why cord-derived stem cell trials cannot be substituted for tissue-allograft evidence

Some international studies grow isolated umbilical cord cells in a laboratory before administration. Those culture-expanded products differ substantially from non-expanded donated tissue. Their cell numbers, manufacturing, biological properties, and regulatory pathways differ. They are not used here as evidence that a non-expanded cord-tissue allograft has the same effectiveness.

Exosomes: can cell-derived signals support the injured knee?

Exosomes are a type of extracellular vesicle released by cells. They carry signaling molecules and are not living stem cells. Researchers are investigating whether selected vesicles can influence inflammatory responses and cartilage-cell behavior. A preparation containing extracellular vesicles is also not necessarily identical to a purified, characterized exosome product.

Our exosomes and osteoarthritis article discusses how these signals may participate in joint disease and repair. That biological rationale is relevant to pain and cartilage injury after dislocation, but the effect of a particular product in patients still requires direct testing.

2025 human study of umbilical cord cell-derived exosomes

Wang and colleagues combined laboratory and animal work with an early human dose-ranging study involving 41 patients and 45 osteoarthritic knees. All treatment groups received cord cell-derived exosomes at different doses. The investigators reported improvements in some symptom measures and exploratory MRI findings, without major safety signals during the reported follow-up. (26)

The important limitation is the absence of a saline or sham control. Although described as randomized and double-blind, the clinical comparison was between active doses. It cannot establish benefit over placebo, and the small study cannot establish broad or long-term safety. These were osteoarthritic knees, not a trial of recurrent patellar dislocation.

The exosomes were obtained from laboratory-grown source cells; the injected material was a cell-derived vesicle preparation, not live culture-expanded stem cells. That distinction also prevents extrapolation to uncharacterized commercial products or ordinary cord-tissue injections.

A placebo-controlled vesicle trial gives an essential comparison

A separate 2024 triple-blind trial studied 31 people with bilateral knee osteoarthritis, comparing placental MSC-derived extracellular vesicles in one knee with saline in the other. The vesicle injection did not improve symptoms or MRI findings beyond placebo. (27)

Placental vesicles are not identical to umbilical cord-derived exosomes. This negative result does not settle every possible product, dose, or schedule. It does show why improvement from baseline alone cannot establish effectiveness. Neither this trial nor the cord-derived study demonstrated restoration of patellar stability.

How do these preparations differ?

Preparation What it contains or represents Relevance to this problem
PRP Platelets concentrated from the patient’s blood Some research on patellofemoral pain; not established prevention of redislocation
Bone marrow concentrate A mixture of marrow cells and other components, with a small MSC population OA symptom research cannot be treated as proof of MPFL repair
Donated cord/Wharton’s jelly tissue A processed donor-tissue preparation whose composition depends on processing Preliminary knee-OA observations; stabilization benefit remains unproven
Isolated cord-derived MSCs A distinct cellular product, sometimes expanded in a laboratory Not interchangeable with non-expanded tissue; outside the supportive treatment evidence used here
Exosomes/extracellular vesicles Cell-derived signaling particles; not living cells Early, product-specific clinical research with mixed findings; no established redislocation prevention

Where our bone marrow research fits

Our published knee-osteoarthritis research evaluated a series of four bone marrow concentrate injections and reported short-term symptom improvements. It was an uncontrolled study, not a randomized comparison of BMC against donated cord tissue or exosomes. It did not establish cartilage regeneration or patellar stabilization. (28)

I consider this distinction important: a patient may feel better without the mechanical cause of repeated slipping having been corrected. Treatment should be evaluated against the outcome it is supposed to achieve.

What U.S. patients should understand about donated products and exosomes

The FDA states that the regenerative products addressed in its consumer guidance, including Wharton’s jelly and umbilical cord products, have not been approved for orthopedic conditions. The FDA also states that there are no FDA-approved exosome products. (29) (30)

Donor screening, tissue-bank registration, or publication of a study does not establish that a product is FDA-approved or legally marketed for a particular joint injection. Applicable regulatory requirements depend on the product, processing, intended use, and investigational status. Donated tissue and cell-derived products can carry infection, inflammatory, immune, and other risks. This research discussion does not imply that our clinic provides a specific investigational product. (29)

Which knee problem is the treatment intended to address?

A patient with a stable kneecap and residual patellofemoral pain has a different research question from a patient whose patella repeatedly dislocates because of ligament insufficiency and high-risk anatomy. Donated tissue and exosome research is most appropriately discussed in relation to the specific painful or damaged tissue, while the mechanical instability receives its own assessment.

For tendon pain below the kneecap, see our patellar tendinopathy and chondromalacia article. Tendon pain does not by itself demonstrate that the kneecap is dislocating. Our broader injection comparison explains why the diagnosis and actual preparation matter.

Returning to sport requires more than waiting

A calendar date alone does not show that the knee is ready for pivoting, landing, or contact. The assessment should consider swelling, motion, strength, single-leg control, confidence, and the ability to tolerate progressively demanding sport tasks. Persistent apprehension or another slipping episode deserves reassessment. The AOSSM/PFF consensus emphasizes evaluating the history, physical findings, and functional context together. (15)

The treatment decision begins by identifying whether the main problem is instability, pain, an associated cartilage injury, or a combination. Rehabilitation can improve control and capacity. Surgery can improve stability in appropriately selected patients. Donated cord tissue and exosomes provide research possibilities for the biological side of knee injury. They should be judged by evidence for the actual preparation and diagnosis, while rehabilitation and indicated stabilization address the mechanical problem.

References

1 Blønd L, Askenberger M, Stephen J, et al. Management of first-time patellar dislocation: The ESSKA 2024 formal consensus—Part 1. Knee Surg Sports Traumatol Arthrosc. 2025;33(5):1925–1932. doi:10.1002/ksa.12620.

2 British Orthopaedic Association. BOASt—Assessment and Management of First Time Lateral Patellar Dislocation (FTLPD). December 2024. Accessed November 14, 2026.

3 Huntington LS, Webster KE, Devitt BM, Scanlon JP, Feller JA. Factors Associated With an Increased Risk of Recurrence After a First-Time Patellar Dislocation: A Systematic Review and Meta-analysis. Am J Sports Med. 2020;48(10):2552–2562. doi:10.1177/0363546519888467.

4 Wierer G, Krabb N, Kaiser P, et al. The Patellar Instability Probability Calculator: A Multivariate-Based Model to Predict the Individual Risk of Recurrent Lateral Patellar Dislocation. Am J Sports Med. 2022;50(2):471–477. doi:10.1177/03635465211063176.

5 Heighes LA, Abelleyra Lastoria DA, Beni R, Iftikhar A, Hing CB. The relationship between joint hypermobility and patellar instability: A systematic review. J Orthop. 2024;56:40–49. doi:10.1016/j.jor.2024.05.005.

6 Eysturoy NH, Husum HC, Ingelsrud LH, Blønd L, Barfod KW. Correlation Between Radiological Measurements for Patellar Instability and Patient-Reported Outcome Measurements in Adolescents: A Study From the Faroese Knee Cohort. Am J Sports Med. 2025;53(1):172–180. doi:10.1177/03635465241295381.

7 Harris G, Patel N, Lobaton GO, Cabrera C, Quintero D, Baraga M, Jose J. Abnormal lateral meniscal signal in MRI after patellar dislocation does not indicate a meniscal tear: MR findings with surgical correlation. J Orthop. 2024. doi:10.1016/j.jor.2024.06.008.

8 Balcarek P, Blønd L, Beaufils P, et al. Management of first-time patellar dislocation: The ESSKA 2024 formal consensus—Part 2. Knee Surg Sports Traumatol Arthrosc. 2025;33(12):4197–4206. doi:10.1002/ksa.12637.

9 Małecki K, Fabiś J, Flont P, Fabiś-Strobin A, Niedzielski K. Assessment of knee flexor muscles strength in patients with patellar instability and its clinical implications for the non-surgical treatment of patients after first patellar dislocation—pilot study. BMC Musculoskelet Disord. 2021;22:740. doi:10.1186/s12891-021-04636-4.

10 Habersack A, Kraus T, Kruse A, Regvar K, Maier M, Svehlik M. Gait Pathology in Subjects with Patellofemoral Instability: A Systematic Review. Int J Environ Res Public Health. 2022;19(17):10491.

11 Brightwell BD, Stone A, Li X, Hardy P, Thompson K, Noehren B, Jacobs C. Blood flow Restriction training After patellar INStability (BRAINS Trial). Trials. 2022;23:88. doi:10.1186/s13063-022-06017-1.

12 Smith TO, Gaukroger A, Metcalfe A, Hing CB. Surgical versus non-surgical interventions for treating patellar dislocation. Cochrane Database Syst Rev. 2023;1:CD008106. doi:10.1002/14651858.CD008106.pub4.

13 Senese M, Smith V. Minimizing Redislocation Rates and Restoring Function After Patella Dislocation: A Critically Appraised Topic. J Sport Rehabil. 2025;34(2):163–170. doi:10.1123/jsr.2023-0426.

14 Straume-Næsheim TM, Randsborg PH, Nilsgård TL, Årøen A. Medial Patellofemoral Ligament Reconstruction vs Nonoperative Treatment for Recurrent Lateral Patellar Dislocation: Three-Year Results From a Randomized Controlled Trial. Am J Sports Med. 2026;54(4):773–779. doi:10.1177/03635465261416931.

15 Post WR, Fithian DC. Patellofemoral Instability: A Consensus Statement From the AOSSM/PFF Patellofemoral Instability Workshop. Orthop J Sports Med. 2018;6(1):2325967117750352. doi:10.1177/2325967117750352.

16 Leclerc JT, Dartus J, Labreuche J, et al. Complications and outcomes of trochleoplasty for patellofemoral instability: A systematic review and meta-analysis of 1000 trochleoplasties. Orthop Traumatol Surg Res. 2021;107(7):103035. doi:10.1016/j.otsr.2021.103035.

17 Zhou ML, Cruz CA, Johnson ZA, Bottoni CR. Outcomes of Patellar Stabilization Utilizing a Combined Arthroscopic and Open Technique: A Retrospective Review With 5-Year Follow-up. Orthop J Sports Med. 2022;10(2):23259671211068404. doi:10.1177/23259671211068404.

18 Chalidis B, Pitsilos C, Davitis V. The Role of Platelet-Rich Plasma (PRP) in the Treatment of Patellofemoral Arthritis and Anterior Knee Pain: A Systematic Review. Int J Mol Sci. 2025;26(18):9006. doi:10.3390/ijms26189006.

19 Franceschi C, Abu Salem Y, Conte P, et al. Are orthobiologics a plausible therapeutic option for patello-femoral pathology? A systematic review of clinical and radiological outcomes. Front Bioeng Biotechnol. 2026;14:1842090. doi:10.3389/fbioe.2026.1842090.

20 Marleau AM, Pearl JR, Juarez P, et al. Critical evaluation of compositions and clinical relevance of Wharton’s jelly-derived biologics. J Transl Med. 2026;24:189. doi:10.1186/s12967-025-07612-x.

21 Gupta A, El-Amin SF III, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cord-derived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res. 2020;15:49. doi:10.1186/s13018-020-1553-7.

22 Gupta A, Rodriguez HC, Potty AG, Levy HJ, El-Amin SF III. Treatment of Knee Osteoarthritis with Intraarticular Umbilical Cord-Derived Wharton’s Jelly: A Case Report. Pharmaceuticals (Basel). 2021;14(9):883. doi:10.3390/ph14090883.

23 Davis JM, Sheinkop MB, Barrett TC. Evaluation of the Efficacy of Cryopreserved Human Umbilical Cord Tissue Allografts to Augment Functional and Pain Outcome Measures in Patients with Knee Osteoarthritis: An Observational Data Collection Study. Physiologia. 2022;2(3):109–120. doi:10.3390/physiologia2030010.

24 Gupta A, Maffulli N. Allogenic Umbilical Cord Tissue for Treatment of Knee Osteoarthritis. Sports Med Arthrosc Rev. 2022;30(3):162–165. doi:10.1097/JSA.0000000000000350.

25 Aratikatla A, Maffulli N, Gupta M, Potti IA, Potty AG, Gupta A. Wharton’s jelly and osteoarthritis of the knee. Br Med Bull. 2024;149(1):13–31. doi:10.1093/bmb/ldad030.

26 Wang Y, Kong Y, Du J, et al. Injection of human umbilical cord mesenchymal stem cells exosomes for the treatment of knee osteoarthritis: from preclinical to clinical research. J Transl Med. 2025;23:641. doi:10.1186/s12967-025-06623-y.

27 Bolandnazar NS, Raeissadat SA, Haghighatkhah H, et al. Safety and efficacy of placental mesenchymal stromal cells-derived extracellular vesicles in knee osteoarthritis: a randomized, triple-blind, placebo-controlled clinical trial. BMC Musculoskelet Disord. 2024;25:856. doi:10.1186/s12891-024-07979-w.

28 Shaw B, Darrow M, Derian A. Short-Term Outcomes in Treatment of Knee Osteoarthritis With 4 Bone Marrow Concentrate Injections. Clin Med Insights Arthritis Musculoskelet Disord. 2018;11:1179544118781080. doi:10.1177/1179544118781080.

29 U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. June 3, 2021. Accessed November 14, 2026.

30 U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. July 22, 2020. Accessed November 14, 2026.